{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"-CMV reactivation will be defined as a positive test for CMV viremia as determined by an antigenemia assay or quantitative PCR that results in the administration of antiviral treatment directed against CMV","groups":[{"description":"-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10\\^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10\\^6 CD34+ cells/kg and at least ≥ 2 x 10\\^6 CD34+ cells/kg from the combined collections.","id":"OG000","title":"Arm 1: Donors"},{"description":"-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0","id":"OG001","title":"Arm 2: Recipients"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"-Donors are not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 1 year after transplantation","title":"Incidence of CMV Reactivation After Transplantation of Hematopoietic Cells Mobilized With BL-8040 in CMV Seropositive Recipients","type":"SECONDARY","unitOfMeasure":"Participants"}